The Power of Prevention: Detecting Diabetes Before It Strikes
SAN DIEGO, Nov. 20, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho, an expert in clinical and laboratory medicine with deep experience in healthcare information systems and data analytics.
In the episode titled "Don't Wait for the Wake-Up Call," Dr. Ding explains why early detection of diabetes is a clinical and economic priority. With diabetes affecting millions of people worldwide – many undiagnosed until complications arise – early testing offers a critical opportunity to shift care from reactive to proactive. Dr. Ding shares how modern laboratory platforms and emerging biomarkers are helping clinicians intervene sooner, personalize care and prevent long-term harm.
Key insights include:
- Early action saves lives: Detecting diabetes before complications occur changes the patient's health trajectory.
- Beyond glucose: Emerging biomarkers like C-peptide, pro-insulin and adiponectin offer a more complete metabolic picture.
- Smarter labs, faster answers: Automation-ready platforms deliver reliable results quickly, supporting timely clinical decisions.
- Economic impact: Early testing reduces costly interventions and aligns with value-based care models.
- Equity in care: Tailored testing strategies ensure accurate diagnosis across diverse populations.
This episode underscores how collaboration between labs and clinicians can help close the loop between diagnostics and care – empowering better outcomes and healthier futures.
The QuidelOrtho Science Bytes podcast is available on major streaming platforms and at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
Media@QuidelOrtho.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-power-of-prevention-detecting-diabetes-before-it-strikes-302621120.html
SOURCE QuidelOrtho Corporation
Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Nachrichten zu Quidel Corp.
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu Quidel Corp.
| Datum | Rating | Analyst | |
|---|---|---|---|
| 22.01.2018 | Quidel Overweight | Barclays Capital | |
| 18.07.2017 | Quidel Buy | Canaccord Adams | |
| 25.04.2017 | Quidel Hold | Canaccord Adams | |
| 08.01.2016 | Quidel Buy | Canaccord Adams | |
| 02.09.2015 | Quidel Overweight | Barclays Capital |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 22.01.2018 | Quidel Overweight | Barclays Capital | |
| 18.07.2017 | Quidel Buy | Canaccord Adams | |
| 08.01.2016 | Quidel Buy | Canaccord Adams | |
| 02.09.2015 | Quidel Overweight | Barclays Capital | |
| 04.01.2011 | Quidel outperform | Wedbush Morgan Securities Inc. |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 25.04.2017 | Quidel Hold | Canaccord Adams | |
| 03.03.2011 | Quidel neutral | Wedbush Morgan Securities Inc. | |
| 30.09.2009 | Quidel market perform | William Blair |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 29.08.2006 | Update Quidel Corp.: Strong Sell | Matrix Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Quidel Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen


